Prandin: Rapid Postprandial Glucose Control for Type 2 Diabetes
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.64 | $49.16 (0%) | 🛒 Add to cart |
| 60 | $1.45 | $98.32 $87.29 (11%) | 🛒 Add to cart |
| 90 | $1.39 | $147.48 $125.41 (15%) | 🛒 Add to cart |
| 120 | $1.36 | $196.64 $163.53 (17%) | 🛒 Add to cart |
| 180 | $1.33 | $294.96 $239.78 (19%) | 🛒 Add to cart |
| 270 | $1.31 | $442.45 $354.16 (20%) | 🛒 Add to cart |
| 360 | $1.30
Best per pill | $589.93 $467.53 (21%) | 🛒 Add to cart |
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.68 | $80.26 (0%) | 🛒 Add to cart |
| 60 | $2.51 | $160.52 $150.49 (6%) | 🛒 Add to cart |
| 90 | $2.46 | $240.79 $221.73 (8%) | 🛒 Add to cart |
| 120 | $2.43 | $321.05 $291.95 (9%) | 🛒 Add to cart |
| 180 | $2.41 | $481.57 $434.42 (10%) | 🛒 Add to cart |
| 270 | $2.39
Best per pill | $722.36 $645.11 (11%) | 🛒 Add to cart |
| 360 | $2.39 | $963.15 $860.82 (11%) | 🛒 Add to cart |
Synonyms | |||
Prandin (repaglinide) is an oral antihyperglycemic agent indicated for the management of type 2 diabetes mellitus. As a meglitinide class medication, it functions primarily by stimulating insulin secretion from pancreatic beta cells, offering a targeted approach to postprandial (after-meal) glucose elevation. It is typically prescribed as an adjunct to diet and exercise when glycemic control is not achieved through lifestyle modifications alone. Prandin provides a flexible dosing regimen that aligns with meal patterns, making it a practical option for patients with irregular eating schedules.
Features
- Active ingredient: Repaglinide
- Available in tablet strengths: 0.5 mg, 1 mg, and 2 mg
- Rapid onset of action, typically within 30 minutes of ingestion
- Short duration of effect, minimizing the risk of prolonged hypoglycemia
- Administered orally, immediately before main meals
- Not indicated for use in type 1 diabetes or diabetic ketoacidosis
Benefits
- Effectively lowers postprandial blood glucose levels, reducing HbA1c over time.
- Flexible dosing allows patients to skip doses when meals are omitted, enhancing adherence and safety.
- Rapid action and short half-life minimize the risk of interprandial or fasting hypoglycemia.
- Can be used as monotherapy or in combination with metformin for synergistic glycemic control.
- Suitable for patients with renal impairment, as it is primarily hepatically metabolized.
- Provides an alternative for patients who cannot tolerate or have contraindications to sulfonylureas.
Common use
Prandin is commonly prescribed for adult patients with type 2 diabetes mellitus who have not achieved adequate glycemic control through diet, exercise, or other oral antihyperglycemic agents. It is particularly beneficial for individuals who experience significant postprandial glucose excursions and those with irregular meal patterns. It may be used as a first-line agent or as an add-on therapy, often in combination with biguanides like metformin, when additional glycemic control is necessary.
Dosage and direction
The recommended starting dose for Prandin is 0.5 mg taken orally within 30 minutes before each main meal. Dosage should be individualized based on glycemic response and meal frequency, with a maximum recommended total daily dose of 16 mg. Patients should be instructed to take the medication only when they plan to eat; if a meal is skipped, the corresponding dose should also be omitted. Dose titration should occur at weekly intervals based on self-monitored blood glucose levels, with adjustments made in increments of 0.5 mg or 1 mg per meal.
Precautions
Patients should be advised to monitor blood glucose regularly to avoid hypoglycemia, especially when initiating therapy or changing doses. Use with caution in patients with hepatic impairment, as repaglinide is extensively metabolized by the liver. Elderly patients and those with adrenal or pituitary insufficiency may be more susceptible to hypoglycemia. It is important to emphasize adherence to dietary recommendations, regular physical activity, and routine HbA1c testing. Alcohol consumption may increase the risk of hypoglycemia and should be avoided or limited.
Contraindications
Prandin is contraindicated in patients with known hypersensitivity to repaglinide or any excipients in the formulation. It is also contraindicated in patients with type 1 diabetes mellitus or diabetic ketoacidosis, as it is not effective under these conditions. Concomitant use with gemfibrozil is contraindicated due to a significant interaction that increases repaglinide plasma concentrations and the risk of hypoglycemia.
Possible side effect
The most frequently reported adverse reaction is hypoglycemia, which may manifest as dizziness, sweating, tremor, headache, and irritability. Other common side effects include upper respiratory tract infection, nausea, diarrhea, and arthralgia. Less frequently, allergic skin reactions, visual disturbances, and elevated liver enzymes have been observed. Severe hypoglycemia, although rare, requires immediate medical attention.
Drug interaction
Prandin may interact with several medications that affect its metabolism or glycemic effects. CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase repaglinide levels, while inducers (e.g., rifampin) may decrease its efficacy. Concomitant use with other glucose-lowering agents, including insulin, may potentiate hypoglycemia. Beta-blockers and other sympatholytic agents can mask hypoglycemic symptoms. Gemfibrozil is contraindicated due to a strong interaction. NSAIDs, salicylates, and monoamine oxidase inhibitors may also enhance the hypoglycemic effect.
Missed dose
If a dose is missed before a meal, it should be omitted entirely. The patient should not take an extra dose to make up for the missed one, as this may increase the risk of hypoglycemia. The next dose should be taken as scheduled with the next meal. Patients should be educated on the importance of dose timing in relation to meals to optimize efficacy and safety.
Overdose
An overdose of Prandin may lead to severe hypoglycemia, characterized by symptoms such as confusion, seizures, loss of consciousness, and coma. Management consists of immediate glucose administration, either orally or intravenously, depending on the patient’s consciousness level. Continuous glucose monitoring and supportive care are essential, as hypoglycemia may recur due to the medication’s duration of action. In cases of intentional overdose, gastric lavage and activated charcoal may be considered if presented early.
Storage
Prandin tablets should be stored at room temperature, between 15°C and 30°C (59°F–86°F), in a tightly closed container, and protected from moisture and light. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Unused medication should be disposed of properly in accordance with local regulations.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized recommendations based on your individual health status and needs. Do not initiate, adjust, or discontinue any medication without consulting your physician.
Reviews
Clinical studies and patient reports indicate that Prandin is effective in reducing postprandial glucose levels and HbA1c, with many users appreciating its flexibility around meal times. Some patients note occasional hypoglycemia, particularly during dose titration. Healthcare providers often recommend it for its rapid action and safety profile in specific patient populations, such as those with renal impairment. Overall, it is regarded as a valuable option in the type 2 diabetes treatment arsenal.